{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:38:00Z","timestamp":1792291080713,"version":"4.4.0"},"reference-count":84,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2003,9,26]],"date-time":"2003-09-26T00:00:00Z","timestamp":1064534400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2003,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Functional imaging of the dopamine transporter (DAT) defines integrity of the dopaminergic system and has its main clinical application in patients with mild, incomplete, or uncertain parkinsonism. Imaging with specific single positron emission computerised tomography ligands for DAT (FP\u2010CIT, \u03b2\u2010CIT, IPT, TRODAT) provides a marker for presynaptic neuronal degeneration. Striatal uptake correlates with disease severity, in particular bradykinesia and rigidity, and monitoring of progression assists in clinical trials of potential neuroprotective drugs. DAT imaging is abnormal in idiopathic Parkinson's disease, multiple system atrophy and progressive supranuclear palsy and does not distinguish between these disorders. Dopamine loss is seen even in the earliest clinical presentations of true parkinsonism; a normal scan suggests an alternative diagnosis such as essential tremor, vascular parkinsonism (unless there is focal basal ganglia infarction), drug\u2010induced parkinsonism, or psychogenic parkinsonism. Congruence between working clinical diagnosis and DAT imaging increases over time in favour of baseline DAT imaging results. Additional applications are characterising dementia with parkinsonian features (abnormal results in dementia with Lewy bodies, normal in Alzheimer's disease); and differentiating juvenile\u2010onset Parkinson's disease (abnormal DAT) from dopa\u2010responsive dystonia (normal DAT). \u00a9 2003 Movement Disorder Society<\/jats:p>","DOI":"10.1002\/mds.10592","type":"journal-article","created":{"date-parts":[[2003,12,10]],"date-time":"2003-12-10T05:00:27Z","timestamp":1071032427000},"page":"1415-1423","source":"Crossref","is-referenced-by-count":189,"title":["Role of dopamine transporter imaging in routine clinical practice"],"prefix":"10.1002","volume":"18","author":[{"given":"Vicky","family":"Marshall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Grosset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2003,9,26]]},"reference":[{"key":"e_1_2_13_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.55.3.181"},{"key":"e_1_2_13_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/113.6.1823"},{"key":"e_1_2_13_4_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.57.8.1497"},{"key":"e_1_2_13_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awf080"},{"key":"e_1_2_13_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/28.2.99"},{"key":"e_1_2_13_7_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.47.3.718"},{"key":"e_1_2_13_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/syn.890090107"},{"key":"e_1_2_13_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.1991.tb02580.x"},{"key":"e_1_2_13_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870120502"},{"key":"e_1_2_13_11_2","first-page":"584","article-title":"Binding of [99mTc]TRODAT\u20101 to dopamine transporters in patients with Parkinson's disease and in healthy volunteers","volume":"41","author":"Mozley PD","year":"2000","journal-title":"J Nucl Med"},{"key":"e_1_2_13_12_2","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1212\/WNL.57.11.2089","article-title":"[123I]beta\u2010CIT SPECT imaging assessment of the rate of Parkinson's disease progression","volume":"57","author":"Marek K","year":"2001","journal-title":"Neurology"},{"key":"e_1_2_13_13_2","first-page":"1703","article-title":"Imaging and quantitation of dopamine transporters with iodine\u2010123\u2010IPT in normal and Parkinson's disease subjects","volume":"38","author":"Kim HJ","year":"1997","journal-title":"J Nucl Med"},{"key":"e_1_2_13_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.62.2.133"},{"key":"e_1_2_13_15_2","first-page":"1129","article-title":"SPECT imaging of dopamine transporters in human brain with iodine\u2010123\u2010fluoroalkyl analogs of beta\u2010CIT","volume":"37","author":"Abi\u2010Dargham A","year":"1996","journal-title":"J Nucl Med"},{"key":"e_1_2_13_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006231-200102000-00006"},{"key":"e_1_2_13_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01728311"},{"key":"e_1_2_13_18_2","first-page":"1879","article-title":"Imaging of dopamine transporters with iodine\u2010123\u2010FP\u2010CIT SPECT in healthy controls and patients with Parkinson's disease","volume":"39","author":"Booij J","year":"1998","journal-title":"J Nucl Med"},{"key":"e_1_2_13_19_2","first-page":"1453","article-title":"Test\/retest reproducibility of iodine\u2010123\u2010betaCIT SPECT brain measurement of dopamine transporters in Parkinson's patients","volume":"38","author":"Seibyl JP","year":"1997","journal-title":"J Nucl Med"},{"key":"e_1_2_13_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8257(199905)14:3<436::AID-MDS1008>3.0.CO;2-J"},{"key":"e_1_2_13_21_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.287.13.1653"},{"key":"e_1_2_13_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8257(199911)14:6<940::AID-MDS1005>3.0.CO;2-Y"},{"key":"e_1_2_13_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8249(200004)47:4<493::AID-ANA13>3.0.CO;2-4"},{"key":"e_1_2_13_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8257(200101)16:1<124::AID-MDS1007>3.0.CO;2-R"},{"key":"e_1_2_13_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s004150050168"},{"key":"e_1_2_13_26_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.46.1.231"},{"key":"e_1_2_13_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.1049"},{"key":"e_1_2_13_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8257(200007)15:4<692::AID-MDS1014>3.0.CO;2-V"},{"key":"e_1_2_13_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410380407"},{"key":"e_1_2_13_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002590000279"},{"key":"e_1_2_13_31_2","first-page":"1175","article-title":"Age\u2010related decline in striatal dopamine transporter binding with iodine\u2010123\u2010\u03b2\u2010CIT SPECT","volume":"36","author":"Van Dyck CH","year":"1995","journal-title":"J Nucl Med"},{"key":"e_1_2_13_32_2","doi-asserted-by":"publisher","DOI":"10.1007\/s007020170019"},{"key":"e_1_2_13_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.1265"},{"key":"e_1_2_13_34_2","doi-asserted-by":"publisher","DOI":"10.1007\/s007020050124"},{"key":"e_1_2_13_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8257(200005)15:3<503::AID-MDS1013>3.0.CO;2-V"},{"key":"e_1_2_13_36_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.55.10.1540"},{"key":"e_1_2_13_37_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.41.9.1422"},{"key":"e_1_2_13_38_2","unstructured":"MarekK.Pramipexole versus Levodopa in the CALM\u2010PD CIT study: effects on Parkinson's disease progression assessed by dopamine transporter imaging.Parkinson Study Group. Presentation EFNS Vienna2002."},{"key":"e_1_2_13_39_2","unstructured":"FahnS.Results of the ELLDOPA (earlier vs. later levodopa) study. Presentation at Seventh International Congress of Parkinson's Disease and Movement Disorders Miami Florida2002."},{"key":"e_1_2_13_40_2","first-page":"1108","article-title":"\u03b2\u2010CIT SPECT versus clinical examination in parkinsonian syndrome: unmasking and early diagnosis","volume":"17","author":"Jennings D","year":"2002","journal-title":"Mov Disord"},{"key":"e_1_2_13_41_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.52.7.1422"},{"key":"e_1_2_13_42_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002590000460"},{"key":"e_1_2_13_43_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-7091-6842-4_2"},{"key":"e_1_2_13_44_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.1256"},{"key":"e_1_2_13_45_2","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8257(200011)15:6<1158::AID-MDS1015>3.0.CO;2-0"},{"key":"e_1_2_13_46_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.10042"},{"key":"e_1_2_13_47_2","first-page":"660","article-title":"Simultaneous SPECT studies of pre\u2010 and postsynaptic dopamine binding sites in baboons","volume":"40","author":"Dresel SH","year":"1999","journal-title":"J Nucl Med"},{"key":"e_1_2_13_48_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.56.1.98"},{"key":"e_1_2_13_49_2","first-page":"165","article-title":"Parkinson's Disease Society Brain Bank, London: overview and research","volume":"39","author":"Daniel SE","year":"1993","journal-title":"J Neural Transm"},{"key":"e_1_2_13_50_2","first-page":"408","article-title":"Differential diagnosis of Parkinson's disease and vascular parkinsonism by (99m)Tc\u2010TRODAT\u20101","volume":"42","author":"Tzen KY","year":"2001","journal-title":"J Nucl Med"},{"key":"e_1_2_13_51_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.10092"},{"key":"e_1_2_13_52_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.180.3.270"},{"key":"e_1_2_13_53_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.165.3.324"},{"key":"e_1_2_13_54_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.62.1.16"},{"key":"e_1_2_13_55_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200225070-00005"},{"key":"e_1_2_13_56_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.37.5.754"},{"key":"e_1_2_13_57_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.40.1.1"},{"key":"e_1_2_13_58_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.47.5.1113"},{"key":"e_1_2_13_59_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.54.5.1050"},{"key":"e_1_2_13_60_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.64.1.18"},{"key":"e_1_2_13_61_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/122.8.1449"},{"key":"e_1_2_13_62_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.73.2.134"},{"key":"e_1_2_13_63_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01728771"},{"key":"e_1_2_13_64_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.58.10.1489"},{"key":"e_1_2_13_65_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410160303"},{"key":"e_1_2_13_66_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1472-8206.1994.tb00808.x"},{"key":"e_1_2_13_67_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(84)91516-2"},{"key":"e_1_2_13_68_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199908000-00007"},{"key":"e_1_2_13_69_2","first-page":"1025","article-title":"Drugs inducing parkinsonism in our environment","volume":"54","author":"Masso MJF","year":"1991","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"e_1_2_13_70_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1982.00510220042009"},{"key":"e_1_2_13_71_2","doi-asserted-by":"publisher","DOI":"10.4065\/73.8.724"},{"key":"e_1_2_13_72_2","first-page":"1108","article-title":"\u03b2\u2010CIT SPECT Imaging to distinguish drug\u2010induced parkinsonism from idiopathic Parkinson's disease exacerbated by drugs: pilot data. Part 1","volume":"17","author":"Friedman JH","year":"2002","journal-title":"Mov Disord"},{"key":"e_1_2_13_73_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(00)00023-2"},{"key":"e_1_2_13_74_2","first-page":"67","article-title":"No loss of striatal dopamine transporters and D2 receptors in patients with autosomal recessive dopa\u2010responsive dystonia","volume":"40","author":"Booij J","year":"1999","journal-title":"J Nucl Med"},{"key":"e_1_2_13_75_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410430614"},{"key":"e_1_2_13_76_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870120330"},{"key":"e_1_2_13_77_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.39.8.1094"},{"key":"e_1_2_13_78_2","first-page":"131","article-title":"Confirming Parkinson's disease with 123I FP\u2010CIT SPECT","volume":"6","author":"O'Sullivan JD","year":"1999","journal-title":"Eur J Neurol"},{"key":"e_1_2_13_79_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.65.1.60"},{"key":"e_1_2_13_80_2","first-page":"994","article-title":"Decreased dopamine transporter binding in Machado\u2010Joseph disease","volume":"41","author":"Yen TC","year":"2000","journal-title":"J Nucl Med"},{"key":"e_1_2_13_81_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.65.2.263"},{"key":"e_1_2_13_82_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.152.9.1359"},{"key":"e_1_2_13_83_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870130219"},{"key":"e_1_2_13_84_2","first-page":"27","article-title":"Clinical Impact of performing SPECT imaging with the dopamine transporter imaging agent 123 I\u2010ioflupane (DaTSCAN) in patients with a clinically uncertain diagnosis of parkinsonian syndromes","volume":"9","author":"Tolosa E","year":"2002","journal-title":"Eur J Neurol"},{"key":"e_1_2_13_85_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-002-0938-7"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.10592","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.10592","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T13:58:38Z","timestamp":1760968718000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.10592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,9,26]]},"references-count":84,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2003,12]]}},"alternative-id":["10.1002\/mds.10592"],"URL":"https:\/\/doi.org\/10.1002\/mds.10592","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,9,26]]}}}